Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Newly Merged Wholesaler Koyo to Get No. 3 Share in Shikoku
April 1, 2002
- 26th JMC General Assembly to Invite Citizens to Participate
April 1, 2002
- Yamanouchi Ties Up with Metabolex for Discovering Diabetes Drugs
April 1, 2002
- Nikken Chemicals to Focus on Drugs
April 1, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 1, 2002
- Sawai Sees 23.48% Reduction in NHI Prices
April 1, 2002
- Only 10-20% of Patients with Osteoporosis Receiving Treatment: WLJ Seminar
April 1, 2002
- Taiyo to Start Strategy to Promote Use of Generics
April 1, 2002
- JACCRO Established to Promote Clinical Trials for Cancer
April 1, 2002
- BUSINESS NEWS IN BRIEF
April 1, 2002
- RenaScience Offers Renal Disease-Related Genes to Companies
April 1, 2002
- Pele Appointed as Japan's Educational Ambassador for ED: Pfizer
April 1, 2002
- Utilization of Medicinal Plants Reported by Korosho
April 1, 2002
- Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
- PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
- Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
- DIAGNOSTIC NEWS IN BRIEF
April 1, 2002
- Ono's Elaspol Recommended for Approval by CDFS Department
April 1, 2002
- Makers Are Not Supplying Sufficient Information to Pharmacies: Survey
April 1, 2002
- Meiji Licenses Carbapenem from Wyeth Lederle
April 1, 2002
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…